Medical AI firm Paige has announced a new partnership with the Breast International Group (BIG), a leading international non-profit organisation dedicated to breast cancer research, to conduct collaborative research aimed at improving breast cancer diagnosis, treatment, and patient outcomes.
The global partnership will leverage Paige’s technology to reduce unnecessary treatment, support better patient stratification, and help standardise the measurement of residual cancer burden.
By combining BIG’s clinical expertise, global academic clinical trials, and comprehensive patient datasets with Paige’s advanced AI capabilities, the partnership aims to generate new insights that enhance biomarker detection, predict response to treatment, and enable the use of AI-driven tools for optimising and personalising therapy to make high-quality care more accessible. AI-powered diagnostics offer the potential to improve testing turnaround time, speed up clinical decision-making, all while sparing both cost and tissue and allow clinicians to focus only on the tests most needed for individualised patient care. The collaboration will focus on addressing areas of unmet clinical need in breast cancer, including rare breast cancer subtypes.
As part of the initiative, Paige and BIG will evaluate the performance of OmniScreen, an AI application that simulates a panel of 1,600 clinically significant cancer biomarkers within 505 genes by analysing H&E-stained images. The primary objective of this evaluation is to identify mutation-associated phenotypes in breast cancer. The research will also explore additional applications of Paige’s technology to help standardise the measurement of residual cancer burden, support more effective patient stratification, and reduce unnecessary treatment. By embedding AI earlier in the diagnostic and research workflows, the partners aim to support more informed clinical decisions and accelerate the delivery of personalised care for people with breast cancer.
“This partnership reflects our belief that AI is no longer just a future promise, it is a present-day solution to some of the most complex challenges in cancer,” said Razik Yousfi, CEO and CTO of Paige. “By combining BIG’s world-class clinical research expertise in breast cancer with Paige’s AI technology, we will accelerate the translation of insights into clinical impact, with the common goal of transforming breast cancer care.”
The collaboration builds on BIG’s legacy of groundbreaking, cooperative clinical research by incorporating advanced digital pathology tools into its scientific portfolio.
“We are excited to collaborate with Paige on this ambitious research effort,” said David Cameron, Chair of the Breast International Group and Professor of Oncology at Edinburgh University, UK. “Our shared mission is to improve the lives of people with breast cancer. By integrating Paige’s innovative AI into our clinical research, we can strengthen our understanding of tumour biology, enhance trial design, and accelerate progress toward more tailored and effective treatments.”